<DOC>
	<DOC>NCT00112021</DOC>
	<brief_summary>This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.</brief_summary>
	<brief_title>A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is obese with a body mass index (BMI) &gt;=30 kg/m^2 to &lt;=50 kg/m^2, and has been obese for at least one year before screening. Usually consumes at least three major meals (morning, midday, and evening) each day. Is currently enrolled in a formal weightloss program. Has had liposuction within 1 year before screening or is planning to have liposuction during the study. Has received any investigational drug within 3 months before screening. Has previously participated in a study using pramlintide.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>Amylin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
</DOC>